Exopert

What Exopert does

Exopert is a Seoul-based biotechnology company developing exosome-based liquid biopsy diagnostics for multi-cancer early detection. The company's core technology combines a proprietary exosome isolation method (EXo-i, a multi-layer size-exclusion chromatography kit that separates exosomes from cell culture media or blood plasma in under 15 minutes without chemical or physical modification) with Surface-Enhanced Raman Spectroscopy (SERS) on gold nano-chips and AI/ML algorithms that classify SERS spectral fingerprints to identify cancer-specific molecular patterns. A flagship platform, the Exosome-SERS-AI Multi-Cancer Early Diagnosis Platform, is reported to detect six cancer types (lung, breast, colorectal, liver, pancreatic, gastric) from a single blood draw with 90.2% sensitivity, 94.4% specificity, 97% AUC, and 87.6%-98% accuracy in tissue-of-origin identification, including 88.1% sensitivity for Stage 1-2 cancers (results published in Nature Communications, April 2023).

Exopert's product portfolio spans research tools and clinical diagnostic assets. Research-side products include EXo-i and ExoTractor exosome isolation kits and exosome isolation services, sold via the company website. Diagnostic-side products include ARM Dx and ExoPred, with the integrated Exosome-SERS-AI platform positioned for clinical deployment. Revenue mechanics today are anchored in research-reagent sales and exosome isolation services; the diagnostic platform is positioned as a future licensing/royalty stream with a stated target price of approximately 300,000 KRW per multi-cancer test. Go-to-market is enterprise/B2B via direct institutional engagement with healthcare providers, cancer research centers, and academic researchers, with international expansion (U.S. market in 2026) supported by collaborations with MD Anderson Cancer Center, Johns Hopkins University, and selection into Johnson & Johnson Innovation JLABS.

The company is co-founded by Korea University professors Yeon Ho Choi (CEO) and Hyun-Gyu Kim. It holds Korean FDA Innovative Medical Device Designation No. 44 for lung cancer diagnostic software and a 5-year NET certification from the Ministry of Health and Welfare, has received a CES Innovation Award (2025), and is backed by Korean venture investors including Mirae Asset Venture Investment, Mirae Asset Capital, Korea Venture Investment, WeVentures, and BSK Investment.

Name

Exopert

Legal name

Exopert

Website

https://exopert.com

Company type

Private

Founded year

2022

Operating status

Operating

Headcount range

11–50 employees

Short description

Exopert is a Seoul-based biotech company that sells exosome isolation research kits (EXo-i, ExoTractor) and is developing an SERS-plus-AI blood-based liquid biopsy platform to simultaneously detect six cancer types from a single blood draw, targeting healthcare providers, cancer research centers, and academic researchers.

Ownership category

akta.pro rank

Product category

Cancer Diagnostics

NAICS

In-Vitro Diagnostic Substance Manufacturing (325413), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Analytical Laboratory Instrument Manufacturing (334516)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Laboratory Analytical Instruments (3826)

akta.pro primary industry

Oncology Diagnostics (tumor profiling, MRD, liquid biopsy) (HLAAALAE)

akta.pro secondary industries

Liquid Biopsy Biomarkers (ctDNA/ctRNA/CTCs/exosomes) (HLAAAMAH), Biomarker Discovery & Validation (omics, assay feasibility, clinical validation) (HLAAAMAA), Proteomics & Biomarker Analytical Testing (HLAGADAG)

Keywords

• Exosome liquid biopsy
• Cancer early detection
• Molecular diagnostics
• Exosome isolation kits
• Multi-cancer screening

Headquarters

HQ city

Seoul

HQ country

South Korea

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Exosome Isolation Products: Sale of research reagents including EXo-i for exosome isolation from cell culture media and blood, ExoTractor for exosome extraction, and related laboratory products.
2. Exosome Isolation Services: Providing exosome isolation services for researchers requiring exosome separation solutions.
3. Diagnostic Platform Licensing: Commercialization of AI-based multi-cancer early diagnosis platform technology including ExoPred for cancer diagnosis. Pursuing regulatory approvals for clinical deployment.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

Exopert develops and commercializes exosome-based liquid biopsy diagnostic platforms for multi-cancer early detection from a single blood sample. The company sells proprietary exosome isolation reagent kits (EXo-i, ExoTractor) and exosome-based diagnostic products (ARM Dx, ExoPred) that combine Surface-Enhanced Raman Spectroscopy (SERS) molecular fingerprint analysis with AI algorithms to simultaneously detect six cancer types (lung, breast, colorectal, liver, pancreatic, and gastric) at 90.2% sensitivity and 94.4% specificity.

Differentiator

Problem solved

Functional benefit

Brands

• Exo-i: High purity exosome isolation product using multi-layer size-exclusion chromatography for rapid separation of exosomes from cell culture media and blood within 15 minutes
• ExoTractor
• ARM Dx
• ExoPred

Products and services

• EXo-i A proprietary exosome isolation kit using multi-layer size-exclusion chromatography to rapidly (<15 minutes) extract high-purity exosomes from cell culture media or blood plasma without chemical or physical modification. Validated to remove 91.1% albumin, 92.6% ApoB, and 92% ApoA while preserving exosome markers (CD9, CD63, CD81, Alix, Annexin V, Annexin A1, Flotillin-1, TSG101) per MISEV2018 guidelines. Sold to researchers and clinical laboratories for exosome isolation applications.
• ExoTractor Exosome isolation product in Exopert's product lineup, marketed alongside EXo-i for exosome research applications including extraction from cell culture media, plasma, and serum.
• ARM Dx Listed as a diagnostic product in Exopert's portfolio, intended for exosome-based disease diagnosis.
• ExoPred Exosome-based disease diagnosis product that uses molecular fingerprinting signals from blood exosomes to detect and classify cancers, leveraging SERS analysis and AI algorithms for multi-cancer detection.
• Exosome Isolation Service Exosome isolation service for researchers requiring high-purity exosome separation solutions from cell culture media, plasma, or serum samples.

Quantifiable outcome

• 90.2% sensitivity and 94.4% specificity for multi-cancer detection across 6 cancer types (lung, breast, colorectal, liver, pancreatic, gastric)
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Seven partnerships are on record, tiered core and minor.

• Johnson & Johnson Innovation JLABScoreStrategic or Co-development Partner · 30 September 2025Exopert selected for JLABS innovation incubator program, providing access to resources and mentorship for accelerating the company's innovation and commercialization efforts.
• Johns Hopkins UniversitycoreStrategic or Co-development Partner · 30 May 2025Research agreement with Johns Hopkins University for the multi-cancer early diagnosis platform. Joint research to advance the AI-powered exosome-based liquid biopsy technology for global cancer patient diagnosis.
• MD Anderson Cancer CentercoreStrategic or Co-development Partner · 12 April 2024Research collaboration with Dr. Samir Hanash at MD Anderson Cancer Center for effectiveness analysis of AI-based multi-cancer diagnosis research. Exopert uses its proprietary equipment and technology to analyze samples from MD Anderson's patient cohort, aiming to strengthen AI-based exosome and Raman signal-based liquid biopsy technology for global cancer diagnosis.
• Korea University ( 고려대학교 )coreStrategic or Co-development Partner
• Korea University Medical Center ( 고려대학교 의료원 )minorStrategic or Co-development PartnerResearch partner institution listed on the company website.
• Gangnam Severance Hospital ( 강남세브란스병원 )minorStrategic or Co-development PartnerMajor Korean hospital listed as a partner on the company website for research collaboration.
• Seoul Bio Hub ( 서울바이오허브 )minorStrategic or Co-development PartnerKorean biotech incubator/hub listed as a partner on the company website.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• System Biosciences (SBI): SBI is a specialist in exosome research tools and services (isolation kits, characterization reagents, engineered exosomes). It competes directly with Exopert's EXo-i and ExoTractor research-reagent business.
• Freenome: Freenome is developing a blood-based multi-cancer screening test using a multiomics (genomics + proteomics) + AI approach. Like Exopert, it is pursuing single-blood-draw early detection of multiple cancers, making it a direct technology-and-use-case peer.
• GRAIL: GRAIL's Galleri test is a leading blood-based multi-cancer early-detection assay (methylation-based). Exopert competes head-to-head in the multi-cancer screening category using a different biology (exosomes + SERS + AI) but targeting the same clinical use case and customer (primary-care/oncology prescribers).

Broad incumbents

• Natera: Natera offers blood-based cancer tests (Signatera for MRD) and reproductive health diagnostics. Its cfDNA-based oncology franchise overlaps Exopert's liquid biopsy category and serves similar oncology and research-customer segments.
• Exact Sciences: Exact Sciences (Cologuard, Oncotype DX, and acquired Thrive Earlier Detection) is a leading cancer diagnostics company pursuing multi-cancer screening. It is a broad incumbent in non-invasive cancer detection with overlapping end customers.
• Guardant Health: Guardant Health offers blood-based liquid biopsy tests (Guardant360, Guardant Reveal) for oncology. While primarily ctDNA-focused and single-cancer applications, it competes in the same liquid biopsy/cancer diagnostics market Exopert targets.
• Bio-Techne: Bio-Techne (including its Exosome Diagnostics division historically) supplies exosome isolation reagents, ELISA kits, and proteomics tools—directly overlapping Exopert's EXo-i reagent product line and serving the same academic and translational research customers.

Emerging players

• NanoFCM: NanoFCM manufactures nano-flow cytometry instruments for single-exosome and nanoparticle analysis, an enabling technology in the exosome research workflow that Exopert's customers use alongside EXo-i for downstream characterization.

Regional players

• MiRXES: MiRXES is a Singapore-based molecular diagnostics company specializing in microRNA-based liquid biopsy for early cancer detection. It is the most direct regional (Asia-based) multi-cancer screening peer to Exopert, sharing both geography and target customer base.
• Hummingbird Bioscience: Hummingbird Bioscience is a Singapore-headquartered precision biotherapeutics company. While a therapeutics developer rather than diagnostics, it is a comparable Asian biotech of similar size that has built US collaborations and is a relevant regional peer for benchmarking.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@exopertco
• LinkedInlinkedin.com/company/exopert

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Exopert